Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient [Yahoo! Finance]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: Yahoo! Finance
its lead candidate, HT-001, who was experiencing papulopustular eruptions (PPEs). Notably, PPEs are a common and debilitating side effect of EGFR inhibitor (EGFRI) therapy in cancer patients. Hoth's HT-001 Demonstrates Superior Efficacy in PPEs Treatment In this groundbreaking case, the 59-year-old female patient undergoing treatment for metastatic breast cancer witnessed significant improvement in symptoms just one week after receiving the novel therapeutic. Based on the rapid healing of lesions and relief of discomfort, the patient discontinued treatment after just one week. Importantly, no new lesions appeared over the next three weeks, underscoring HT-001's potential as a safe and effective treatment for EGFRI-related PPEs. Such results mark a significant milestone in addressing a serious unmet medical need experienced by cancer patients receiving EGFRI therapy. If successfully developed, the candidate could greatly improve the quality of life for cancer patients suffering f
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve AssetPR Newswire
- Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment StudyPR Newswire
- Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway [Yahoo! Finance]Yahoo! Finance
HOTH
Sec Filings
- 11/20/24 - Form 8-K
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 424B5
- HOTH's page on the SEC website